PDE5A and pulmonary arterial hypertension: Phosphodiesterase type 5 (PDE5) degrades cyclic guanosine monophosphate (cGMP), thereby inhibiting the nitric oxide (NO)-mediated relaxation of smooth muscle and contributing to the development of PAH [31,32,33,34].